[go: up one dir, main page]

AR081542A1 - Composiciones de emulsiones farmaceuticas con bajo contenido de aceite que comprenden un progestageno - Google Patents

Composiciones de emulsiones farmaceuticas con bajo contenido de aceite que comprenden un progestageno

Info

Publication number
AR081542A1
AR081542A1 ARP110101417A ARP110101417A AR081542A1 AR 081542 A1 AR081542 A1 AR 081542A1 AR P110101417 A ARP110101417 A AR P110101417A AR P110101417 A ARP110101417 A AR P110101417A AR 081542 A1 AR081542 A1 AR 081542A1
Authority
AR
Argentina
Prior art keywords
progestagen
understand
compositions
low oil
oil contents
Prior art date
Application number
ARP110101417A
Other languages
English (en)
Inventor
Laura Pickersgill
Hoiser Eva Di
Georg Maria-Achleitner
Original Assignee
Besins Healthcare Lu Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Besins Healthcare Lu Sarl filed Critical Besins Healthcare Lu Sarl
Publication of AR081542A1 publication Critical patent/AR081542A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Composición de administración parenteral en forma de emulsión farmacéutica de aceite en agua, estéril y lista para usar, que comprende entre 0,015 y 0,5% p/v de progesterona; entre 0,5 y 10% p/v de aceite, donde el aceite comprende al menos 85% p/p de un triglicérido; entre 0,0425 y 4,1% p/v de un fosfolípido; entre 80 - 99,4% p/v de un medio acuoso; donde la composición tiene una osmolalidad en el rango de 200 - 1000 mOsm/kg. Uso de la composición mencionada con anterioridad en el tratamiento terapéutico o profiláctico, donde dicho tratamiento comprende la administración intravenosa de la emulsión farmacéutica.
ARP110101417A 2010-04-26 2011-04-25 Composiciones de emulsiones farmaceuticas con bajo contenido de aceite que comprenden un progestageno AR081542A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP10161029 2010-04-26
EP10161032 2010-04-26
EP10161034 2010-04-26
EP10195764 2010-12-17
EP10195766 2010-12-17
EP10195760 2010-12-17

Publications (1)

Publication Number Publication Date
AR081542A1 true AR081542A1 (es) 2012-10-03

Family

ID=44001967

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101417A AR081542A1 (es) 2010-04-26 2011-04-25 Composiciones de emulsiones farmaceuticas con bajo contenido de aceite que comprenden un progestageno

Country Status (22)

Country Link
US (4) US8476252B2 (es)
EP (4) EP2857042B1 (es)
JP (1) JP5886273B2 (es)
KR (1) KR101822680B1 (es)
CN (2) CN102946864A (es)
AR (1) AR081542A1 (es)
AU (1) AU2011246527B2 (es)
BR (1) BR112012027279B1 (es)
CA (2) CA2797141C (es)
EA (1) EA022460B1 (es)
ES (4) ES2531646T3 (es)
GE (1) GEP20166457B (es)
IL (2) IL222710A (es)
MX (1) MX2012012491A (es)
MY (1) MY156858A (es)
NZ (1) NZ603176A (es)
PH (1) PH12012502120B1 (es)
PL (1) PL2563335T3 (es)
PT (1) PT2563335E (es)
SG (1) SG185025A1 (es)
TW (1) TW201138782A (es)
WO (2) WO2011134937A2 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201138782A (en) 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
KR102027613B1 (ko) 2012-02-29 2019-10-01 베. 브라운 멜중엔 악티엔게젤샤프트 호르몬 함유 유화액
TWI651098B (zh) * 2012-02-29 2019-02-21 B 柏藍麥桑根公司 含荷爾蒙的乳劑
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN105263475A (zh) * 2013-03-15 2016-01-20 制药创源有限公司 雷公藤甲素静脉注射乳剂用作免疫调制剂和抗癌药
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
US20160310584A1 (en) * 2013-12-06 2016-10-27 The Broad Institute Inc. Formulations for neoplasia vaccines
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
US10253135B2 (en) * 2014-09-12 2019-04-09 Drexel University Toughening of anhydride cured thermosetting epoxy polymers using grafted triglycerides
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
CA2971786A1 (en) * 2015-03-31 2016-10-06 Fresenius Kabi Deutschland Gmbh Emulsions for parenteral administration
IL302102A (en) 2015-05-20 2023-06-01 Dana Farber Cancer Inst Inc shared neoantigens
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CN106074383B (zh) * 2016-07-27 2019-03-08 武汉科福新药有限责任公司 孕激素药物脂微球注射液及其制备方法
US20180207097A1 (en) * 2017-01-23 2018-07-26 Government Of The United States As Represented By The Secretary Of The Air Force Non-toxic vehicle to solubilize, deliver, and obtain biological activity of steroid hormones at cell, tissue, and organ targets, in vitro and in vivo
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
WO2020123551A1 (en) * 2018-12-10 2020-06-18 Halo Science LLC Stable formulations of anesthetics and associated dosage forms
CN114867467B (zh) 2019-12-20 2025-06-20 费森尤斯卡比奥地利有限公司 用于产生水包油乳剂的方法
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
EP3878434A1 (en) * 2020-03-12 2021-09-15 Lipoid GmbH Sunflower phospholipid composition containing phosphatidylcholine
WO2023034317A1 (en) * 2021-08-30 2023-03-09 Premier Nutrition Company, Llc Sleep-inducing beverage composition, its method of production and the method of use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60258110A (ja) 1984-06-05 1985-12-20 Daigo Eiyou Kagaku Kk 静脈注射可能なプロゲステロン乳化注射液
IL89856A (en) 1989-04-05 1993-05-13 Yissum Res Dev Co Medical emulsions for liphophilic drugs containing a medium-chain triglyceride oil as a carrier
US5364632A (en) * 1989-04-05 1994-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
SE9301171D0 (sv) * 1993-04-07 1993-04-07 Ab Astra Pharmaceutical composition containing lipophilic drugs
SE9403389D0 (sv) 1994-10-06 1994-10-06 Astra Ab Pharmaceutical composition containing derivattves of sex hormones
HK1050317A1 (zh) * 1999-07-22 2003-06-20 Aventisub Ii Inc. 防腐的药物制剂
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6327968B1 (en) 2000-03-17 2001-12-11 Pizza Hut, Inc. System and method for producing par-baked pizza crusts
EP1488785A1 (de) * 2003-06-18 2004-12-22 B. Braun Melsungen Ag Ölemulsion zur postnatalen Hormonsubstitution
WO2005105040A2 (en) 2004-04-26 2005-11-10 Micelle Products, Inc. Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications
ATE439123T1 (de) 2004-07-02 2009-08-15 Novagali Pharma Sa Verwendung von emulsionen zur intra- und periocularen injection
US7473687B2 (en) 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
EP2030622B1 (en) 2005-03-24 2011-02-23 Emory University Indication of dosage of progesterone in the treatment of a traumatic brain injury
CN101605529B (zh) * 2006-02-09 2013-03-13 参天制药株式会社 稳定制剂及它们的制备和使用方法
CN101152186B (zh) * 2007-09-05 2011-07-06 杭州平和安康医药科技有限公司 黄体酮注射液及其制备方法
TW201138782A (en) 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen

Also Published As

Publication number Publication date
PT2563335E (pt) 2015-03-31
AU2011246527A1 (en) 2012-11-15
IL222710A0 (en) 2012-12-31
BR112012027279B1 (pt) 2020-12-29
JP2013525402A (ja) 2013-06-20
IL222710A (en) 2015-11-30
PH12012502120B1 (en) 2018-01-12
CN102946864A (zh) 2013-02-27
PL2563335T3 (pl) 2015-05-29
KR20130069638A (ko) 2013-06-26
CA2797253A1 (en) 2011-11-03
US20140147474A1 (en) 2014-05-29
SG185025A1 (en) 2012-11-29
MX2012012491A (es) 2013-02-15
CA2797141A1 (en) 2011-11-03
US20140335133A1 (en) 2014-11-13
NZ603176A (en) 2014-05-30
BR112012027279A2 (pt) 2018-05-15
EP2563334A2 (en) 2013-03-06
IL222738A0 (en) 2012-12-31
EP2563334B1 (en) 2014-07-16
WO2011134944A3 (en) 2012-02-09
EA022460B1 (ru) 2016-01-29
MY156858A (en) 2016-04-15
AU2011246527B2 (en) 2016-09-15
EA201291108A1 (ru) 2013-04-30
EP2563335A2 (en) 2013-03-06
WO2011134944A2 (en) 2011-11-03
US9572818B2 (en) 2017-02-21
US20110262494A1 (en) 2011-10-27
EP2801353B1 (en) 2016-03-30
EP2857042B1 (en) 2016-08-31
EP2563335B1 (en) 2014-12-17
CN102946865B (zh) 2016-06-22
US8765149B2 (en) 2014-07-01
ES2531646T3 (es) 2015-03-18
CN102946865A (zh) 2013-02-27
CA2797253C (en) 2019-02-05
TW201138782A (en) 2011-11-16
US20110262495A1 (en) 2011-10-27
EP2857042A1 (en) 2015-04-08
PH12012502120A1 (en) 2013-02-04
ES2514690T3 (es) 2014-10-28
WO2011134937A3 (en) 2012-02-02
ES2606585T3 (es) 2017-03-24
ES2576190T3 (es) 2016-07-06
GEP20166457B (en) 2016-04-11
KR101822680B1 (ko) 2018-01-26
WO2011134937A2 (en) 2011-11-03
EP2801353A1 (en) 2014-11-12
JP5886273B2 (ja) 2016-03-16
US8476252B2 (en) 2013-07-02
CA2797141C (en) 2018-05-15
HK1181998A1 (en) 2013-11-22
IL222738A (en) 2015-11-30

Similar Documents

Publication Publication Date Title
AR081542A1 (es) Composiciones de emulsiones farmaceuticas con bajo contenido de aceite que comprenden un progestageno
CR20220108A (es) Nanopartículas lipídicas mejoradas para el suministro de ácidos nucleicos
CL2017001488A1 (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo
BR112018067586A2 (pt) composição administrável oralmente
AR088382A1 (es) Formulaciones de etanercept estabilizadas con xilitol
MX2013007807A (es) Emulsiones de aceite/agua que comprenden alcanos semifluorados.
GT201500086A (es) Análogos de 2'-cloro nucleósido para infección por vhc
BR112014026118A2 (pt) métodos relacionados a composições para cuidados pessoais
PE20180038A1 (es) Composiciones farmaceuticas topicas
PE20131166A1 (es) Formulacion de premezcla de dexmedetomidina
MX377302B (es) Composiciones para el cuidado personal con dos fases benéficas.
MX2019003698A (es) Composicion que comprende al menos una sal farmaceuticamente aceptable de elafibranor soluble en medio acuoso que muestra una absorcion intestinal mejorada.
MX2015016931A (es) Una formulacion de aceite marino que comprende reservatrol o sus derivados para su uso en el tratamiento, retraso y/o prevencion de la enfermedad de alzheimer.
CL2018003110A1 (es) Preparación y dispersión de formulaciones de emulsión estable.
CL2012003341A1 (es) Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.
CL2012003282A1 (es) Composicion farmaceutica topica que comprende, en base al peso total de la composicion a) 0,01 a 0,2% en peso de furoato de mometasona, b) 5 a 18% en peso de hexilenglicol, c) 20 a 40% en peso de agua y d) 25 a 70% en peso de una fase oleosa; y su uso para tratar o prevenir psoriasis, dermatitis atopica, entre otros.
CL2016002400A1 (es) Formulación para higiene personal
BR112019005224A2 (pt) forma de dosagem para alívio prolongado
CL2015001368A1 (es) Metodo para anticoncepcion controlada que comprende administrar una preparacion farmaceutica que comprende levonorgestrel y un inhibidor de la cox; uso de la composicion farmaceutica en la anticoncepcion "a la carta".
PE20170305A1 (es) Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
UY30676A1 (es) Microemulsion aceite/agua de propofol estable y lista para uso
BR112016006485A2 (pt) composições de liberação pulsátil revestidas por compressão
TN2012000505A1 (en) Low-oil pharmaceutical emulsion compositions comprising progestogen
CR20150411A (es) Composiciones farmacéuticas que contienen dexketoprofeno y tramadol
CO2019010902A1 (es) Composición farmacéutica líquida que contiene dantrolene sódico

Legal Events

Date Code Title Description
FC Refusal